IS6809A - Samsettar ónæmisglæðisblöndur - Google Patents
Samsettar ónæmisglæðisblöndurInfo
- Publication number
- IS6809A IS6809A IS6809A IS6809A IS6809A IS 6809 A IS6809 A IS 6809A IS 6809 A IS6809 A IS 6809A IS 6809 A IS6809 A IS 6809A IS 6809 A IS6809 A IS 6809A
- Authority
- IS
- Iceland
- Prior art keywords
- adjuvants
- composite
- composite adjuvants
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24710000P | 2000-11-10 | 2000-11-10 | |
US33034501P | 2001-10-18 | 2001-10-18 | |
PCT/US2001/046943 WO2002038177A2 (en) | 2000-11-10 | 2001-11-08 | Adjuvant combination formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
IS6809A true IS6809A (is) | 2003-05-07 |
Family
ID=26938452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS6809A IS6809A (is) | 2000-11-10 | 2003-05-07 | Samsettar ónæmisglæðisblöndur |
Country Status (26)
Country | Link |
---|---|
US (2) | US20040156820A1 (is) |
EP (1) | EP1343527A2 (is) |
JP (2) | JP2004523483A (is) |
KR (1) | KR100863368B1 (is) |
CN (1) | CN1533285A (is) |
AU (2) | AU2002225972B2 (is) |
BG (1) | BG107798A (is) |
BR (1) | BR0115271A (is) |
CA (1) | CA2429000A1 (is) |
CZ (1) | CZ20031225A3 (is) |
EA (1) | EA004744B1 (is) |
EE (1) | EE200300172A (is) |
EG (1) | EG24378A (is) |
GE (1) | GEP20074077B (is) |
HR (1) | HRP20030355A2 (is) |
HU (1) | HUP0600589A2 (is) |
IL (1) | IL155690A0 (is) |
IS (1) | IS6809A (is) |
MX (1) | MXPA03004071A (is) |
NO (1) | NO20032086L (is) |
NZ (1) | NZ525887A (is) |
PE (1) | PE20020530A1 (is) |
PL (1) | PL366031A1 (is) |
SK (1) | SK5482003A3 (is) |
TW (1) | TWI239848B (is) |
WO (1) | WO2002038177A2 (is) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
CN1934127B (zh) | 2003-12-17 | 2015-08-19 | 杨森阿尔茨海默氏症免疫治疗公司 | Αβ免疫原性肽载体-偶联物及其生产方法 |
WO2006047670A2 (en) * | 2004-10-26 | 2006-05-04 | Wyeth | Methods for assessing antibodies to neurodegenerative disease-associated antigens |
KR100878585B1 (ko) | 2006-06-16 | 2009-01-15 | 국립암센터 | 글루코사민, 글루코사민 유도체 또는 이들의 염을 포함하는항암감작제 |
US9498522B2 (en) | 2008-08-07 | 2016-11-22 | Mercia Pharma Inc. | Immunotherapeutic compositions for the treatment of alzheimer'S disease |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
US5391485A (en) * | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
US5939074A (en) | 1986-12-30 | 1999-08-17 | The United States Of America As Represented By The Department Of Health And Human Services | Multideterminant peptide antigens |
US6294322B1 (en) | 1988-01-26 | 2001-09-25 | The United States Of America As Represented By The Department Of Health And Human Services | Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1 |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5993819A (en) | 1987-09-08 | 1999-11-30 | Duke University | Synthetic vaccine for protection against human immunodeficiency virus infection |
US5019387A (en) * | 1987-09-08 | 1991-05-28 | Duke University | Production of antibodies to HIV |
US5013548A (en) * | 1987-09-08 | 1991-05-07 | Duke University | Production of antibodies to HIV |
US5223254A (en) * | 1987-09-29 | 1993-06-29 | Praxis Biologics, Inc. | Respiratory syncytial virus: vaccines |
CA1340506C (en) * | 1987-11-24 | 1999-04-20 | Nicholas H. Carbonetti | Production of gonorrheal pi proteins and vaccines |
US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
CA2002607C (en) | 1988-11-10 | 2004-01-27 | Gordon G. Wong | Natural killer stimulatory factor |
US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
DE3934366A1 (de) | 1989-10-14 | 1991-04-18 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum |
EP0968721A3 (en) | 1991-12-02 | 2004-02-04 | The Board Of Regents, The University Of Texas System | Use of a composition comprising a peptide for the inhibition of HIV |
US6037135A (en) | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
JPH07504683A (ja) * | 1992-07-08 | 1995-05-25 | シェリング・コーポレーション | Gm−csfのワクチンアジュバントとしての利用 |
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
WO1994021292A1 (en) * | 1993-03-23 | 1994-09-29 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
US5723130A (en) * | 1993-05-25 | 1998-03-03 | Hancock; Gerald E. | Adjuvants for vaccines against respiratory syncytial virus |
US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
US5571515A (en) | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
AUPM543894A0 (en) * | 1994-05-04 | 1994-05-26 | Commonwealth Scientific And Industrial Research Organisation | An adjuvant |
US5679256A (en) * | 1994-06-20 | 1997-10-21 | Rose; Jane Anne | In-situ groundwater clean-up and radionuclide disposal method |
DK0784486T3 (da) * | 1994-10-05 | 2006-08-14 | Univ Vanderbilt | Interleukin-12 som en adjuvans til Paramyxoviridae-vacciner |
US5939075A (en) * | 1994-11-04 | 1999-08-17 | The United States Of America As Represented By The Secretary Of The Army | Mutants of Brucella melitensis |
WO1996026277A1 (en) * | 1995-02-24 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
US6613337B1 (en) * | 1997-02-12 | 2003-09-02 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
JPH09124697A (ja) * | 1995-11-01 | 1997-05-13 | Toagosei Co Ltd | ペプチド及びモノクローナル抗体 |
US6096313A (en) * | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
US5762943A (en) * | 1996-05-14 | 1998-06-09 | Ribi Immunochem Research, Inc. | Methods of treating type I hypersensitivity using monophosphoryl lipid A |
AU724743B2 (en) * | 1996-05-31 | 2000-09-28 | Genetics Institute, Llc | IL-12 as an adjuvant for Bordetella Pertussis vaccines |
US6024965A (en) | 1996-10-18 | 2000-02-15 | Erasums University Rotterdam | Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection |
US6797276B1 (en) * | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US6350456B1 (en) * | 1997-03-13 | 2002-02-26 | Corixa Corporation | Compositions and methods for the prevention and treatment of M. tuberculosis infection |
US6113918A (en) * | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
GB9712347D0 (en) * | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
IS4518A (is) * | 1997-07-09 | 1999-01-10 | Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group | Nýtt lyfjaform fyrir bóluefni |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
JP2002502884A (ja) * | 1998-02-12 | 2002-01-29 | アメリカン・サイアナミド・カンパニー | インターロイキン−12および単純ヘルペスウイルス抗原を含んでなるワクチン |
DE69935507T2 (de) | 1998-04-03 | 2007-12-06 | University Of Iowa Research Foundation | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
GB9907860D0 (en) * | 1999-04-07 | 1999-06-02 | Smithkline Beecham Biolog | Novel compounds |
MXPA01011499A (es) | 1999-05-13 | 2002-06-04 | American Cyanamid Co | Formulaciones de combinacion de adyuvantes. |
US7396535B2 (en) * | 2003-04-25 | 2008-07-08 | Ackerman Alan H | Therapy for obsessive compulsive head banging |
-
2001
- 2001-11-08 AU AU2002225972A patent/AU2002225972B2/en not_active Ceased
- 2001-11-08 AU AU2597202A patent/AU2597202A/xx active Pending
- 2001-11-08 SK SK548-2003A patent/SK5482003A3/sk not_active Application Discontinuation
- 2001-11-08 CN CNA018213863A patent/CN1533285A/zh active Pending
- 2001-11-08 EE EEP200300172A patent/EE200300172A/xx unknown
- 2001-11-08 US US10/416,262 patent/US20040156820A1/en not_active Abandoned
- 2001-11-08 KR KR1020037006366A patent/KR100863368B1/ko not_active IP Right Cessation
- 2001-11-08 PE PE2001001106A patent/PE20020530A1/es not_active Application Discontinuation
- 2001-11-08 MX MXPA03004071A patent/MXPA03004071A/es not_active Application Discontinuation
- 2001-11-08 WO PCT/US2001/046943 patent/WO2002038177A2/en active IP Right Grant
- 2001-11-08 CZ CZ20031225A patent/CZ20031225A3/cs unknown
- 2001-11-08 BR BR0115271-8A patent/BR0115271A/pt not_active IP Right Cessation
- 2001-11-08 EA EA200300557A patent/EA004744B1/ru not_active IP Right Cessation
- 2001-11-08 NZ NZ525887A patent/NZ525887A/en unknown
- 2001-11-08 PL PL01366031A patent/PL366031A1/xx not_active Application Discontinuation
- 2001-11-08 IL IL15569001A patent/IL155690A0/xx unknown
- 2001-11-08 HU HU0600589A patent/HUP0600589A2/hu unknown
- 2001-11-08 EP EP01993474A patent/EP1343527A2/en not_active Withdrawn
- 2001-11-08 CA CA002429000A patent/CA2429000A1/en not_active Abandoned
- 2001-11-08 JP JP2002540759A patent/JP2004523483A/ja active Pending
- 2001-11-08 GE GE5203A patent/GEP20074077B/en unknown
- 2001-11-09 TW TW090127895A patent/TWI239848B/zh active
- 2001-11-10 EG EG2001111183A patent/EG24378A/xx active
-
2003
- 2003-05-05 HR HR20030355A patent/HRP20030355A2/hr not_active Application Discontinuation
- 2003-05-07 IS IS6809A patent/IS6809A/is unknown
- 2003-05-09 NO NO20032086A patent/NO20032086L/no not_active Application Discontinuation
- 2003-05-10 BG BG107798A patent/BG107798A/bg unknown
-
2006
- 2006-10-06 US US11/544,056 patent/US20070025959A1/en not_active Abandoned
-
2009
- 2009-08-21 JP JP2009192001A patent/JP2010001304A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
IL155690A0 (en) | 2003-11-23 |
GEP20074077B (en) | 2007-03-26 |
MXPA03004071A (es) | 2003-09-04 |
BG107798A (en) | 2004-07-30 |
AU2002225972B2 (en) | 2006-06-29 |
SK5482003A3 (en) | 2004-03-02 |
JP2010001304A (ja) | 2010-01-07 |
EA004744B1 (ru) | 2004-08-26 |
BR0115271A (pt) | 2005-12-13 |
NZ525887A (en) | 2005-08-26 |
WO2002038177A2 (en) | 2002-05-16 |
WO2002038177A3 (en) | 2003-01-16 |
PL366031A1 (en) | 2005-01-24 |
JP2004523483A (ja) | 2004-08-05 |
TWI239848B (en) | 2005-09-21 |
CZ20031225A3 (cs) | 2003-10-15 |
CA2429000A1 (en) | 2002-05-16 |
HRP20030355A2 (en) | 2005-04-30 |
EG24378A (en) | 2009-03-26 |
EE200300172A (et) | 2003-06-16 |
KR20040043098A (ko) | 2004-05-22 |
NO20032086L (no) | 2003-07-07 |
NO20032086D0 (no) | 2003-05-09 |
HUP0600589A2 (en) | 2006-11-28 |
KR100863368B1 (ko) | 2008-10-13 |
PE20020530A1 (es) | 2002-06-18 |
AU2597202A (en) | 2002-05-21 |
US20070025959A1 (en) | 2007-02-01 |
EP1343527A2 (en) | 2003-09-17 |
US20040156820A1 (en) | 2004-08-12 |
EA200300557A1 (ru) | 2004-04-29 |
CN1533285A (zh) | 2004-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60135231D1 (de) | Verbundvliesstoff | |
DE60135144D1 (de) | Verbinder | |
DE60143422D1 (de) | Verbinder | |
DE60026949D1 (de) | Verbinder | |
DZ3409A1 (fr) | Association therapeuthique | |
DE60112603T2 (de) | Perkutane aortenklappe | |
NO20025176D0 (no) | Multippelstigerörreaktor | |
NO20032245D0 (no) | Brönnbehandling | |
DE60133295D1 (de) | Sulphoniumsalz-verbindung | |
DE60102506D1 (de) | Verbinder | |
FI20002644A (fi) | Liitäntäalusta | |
DE10196148T1 (de) | Zusammengesetztes Bauelement | |
DE60119758D1 (de) | Verbundsegment | |
DE60131191D1 (de) | Hautdurchdringungsgaskollektor | |
DE60119875D1 (de) | Verbinder | |
DE60129090D1 (de) | Verbundwerkstoff | |
DE60109670D1 (de) | Verbinder | |
DE60106146D1 (de) | Verbinder | |
DE50109748D1 (de) | Hydrolager | |
DE60112673D1 (de) | Verbinder | |
DE60126898D1 (de) | Buschschneider | |
FR2806446B1 (fr) | Turbocompresseur | |
DE60107134D1 (de) | Verbinder | |
NO20024322L (no) | Sekvens | |
DE60132233D1 (de) | Verbundnadel |